FDA Approves First Oral PCSK9 Inhibitor Lipfendra

The US Food and Drug Administration (FDA) has approved Merck's Lipfendra, the world's first oral PCSK9 inhibitor drug, in July 2026. This breakthrough medication is taken as a daily pill and works differently from traditional statins by increasing the liver's ability to remove bad cholesterol already present in the bloodstream.

Lipfendra targets the PCSK9 protein, which typically blocks liver sensors that remove bad cholesterol. When these sensors are depleted, the level of bad cholesterol in the blood increases. By deactivating the PCSK9 protein, Lipfendra allows the sensors to capture and destroy more harmful LDL cholesterol circulating in the bloodstream.

This new oral medication is a game-changer for two specific categories of patients: those who are statin intolerant and high-risk patients who have had a heart attack or are suffering from congenital high cholesterol due to a genetic condition (HeFH). For them, Lipfendra has emerged as a very safe and effective option.